MAST Launch Influenza A Subtyping Kit
MAST have launched the innovative Seeplex Flu A ACE kit for the subtyping of influenza A strains. The first kit of its kind to market, the Seeplex Flu A ACE offers confirmation of Influenza A infection and differentiates with the following markers:
The major benefit of being able to differentiate Influenza A subtypes is that therapy can be targeted for more appropriate use. The guidelines for antiviral drug prescriptions are:
The Seeplex group of products offers customers a single platform for multiple test parameters. The Flu A ACE is the latest in the range of Seeplex products which includes multiplex assays for respiratory viruses (5,12 & 15), meningitis, diarrhoea and STI´s amongst others. The simple to use, rapid, easily integrated platform enables laboratories to implement a lean testing protocol that can reduce hands-on time, staff training and also help make best use of laboratory space.
NOTE: This item is from our 'historic' database and may contain information which is not up to date.
Source : Mast Group Ltd. View Company Information
Posted on September 24, 2009